Allergan Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Seattle

DUBLIN, April 26, 2016 /PRNewswire/ -- Allergan (NYSE: AGN) today announced that its data will be presented during the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington, May 1-5, 2016.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

This data spans retina, ocular surface and glaucoma subspecialties and is reflective of Allergan's global leadership position in eye care.

"Allergan is pleased to be presenting data at ARVO this year. With more than 60 years of eye care experience and 17 mid-to-late stage programs in development, Allergan is committed to advancing research and products for the eye care community," said David Nicholson, Executive Vice President and President of Global R&D Brands at Allergan.

The scheduled times (noted in local Pacific Time) of the 18 Allergan presentations, presentation titles and locations at the Washington State Convention Center are as follows:

Retina:

• The association between onset of self-reported vision impairment and nursing home residence in an older US population
  • Date and Time: Monday, May 2, 2016, 8:30-10:15 AM
  • Room: Main Exhibit Hall
  • Categories: Community aspects of Eye Care and Disease

• Consistency of visual acuity response to anti-VEGF therapy in diabetic macular edema patients: An analysis of DRCR.net Protocol I data
  • Date and Time: Monday, May 2, 2016, 3:45-4:00 PM
  • Room: Tahoma 3
  • Categories: Diabetic Macular Edema Treatment

• Real-World Assessment of Dexamethasone Intravitreal Implant in Diabetic Macular Edema: Interim Analysis from the REINFORCE Study
  • Date and Time: Tuesday, May 3, 2016, 8:30-10:15 AM
  • Room: Main Exhibit Hall
  • Categories: Diabetic Retinopathy and Steroids

• A 12-Month, Open-Label, Multicenter Study to Assess the Safety and Efficacy of Ozurdex 0.7 mg for the Treatment of Macula Edema Related to Branch Retinal Vein Occlusion in Korea; the COBALT Study
  • Date and Time: Tuesday, May 3, 2016, 3:45-5:30 PM
  • Room: Main Exhibit Hall
  • Categories: Macular Edema Clinical & Translational

• Ocular Pharmacokinetics of Brimonidine Drug Delivery System in Rabbits and Monkeys and Its Application in Selection of Dosing Frequency in Human Clinical Trials
  • Date and Time: Monday, May 2, 2016, 11:00 AM-12:45 PM
  • Room: Main Exhibit Hall
  • Categories: AMD & CNV: Clinical & Translational

Ocular Surface:

• Superior efficacy of Lastacaft® versus Pataday in grass- and tree-allergic subjects
  • Date and Time: Sunday, May 1, 2016, 8:30-10:15 AM
  • Room: Main Exhibit Hall
  • Categories: Allergic Conjunctivitis/Corneal Immunology & Infection

• Clinical comparison of gel-type artificial tears
  • Date and Time: Tuesday, May 3, 2016, 8:30-10:15 AM
  • Room: Main Exhibit Hall
  • Categories: Dry Eye II

• Randomized, controlled, crossover trial comparing the impact of sham or intranasal neurostimulation on conjunctival goblet cell degranulation
  • Date and Time: Tuesday, May 3, 2016, 8:30-10:15 AM
  • Room: Main Exhibit Hall
  • Categories: Dry Eye II

• Effects of punctal occlusion on tear protein levels in dry eye patients
  • Date and Time: Tuesday, May 3, 2016, 12:00-12:15 PM
  • Room: 606/607
  • Categories: Dry Eye; Clinical & Epidemiology

• Definition and clinical characteristics of evaporative dry eye in a general population of dry eye patients
  • Date and Time: Thursday, May 5, 2016, 8:00-9:45 AM
  • Room: Main Exhibit Hall
  • Categories: Lacrimal Glands, Meibomian Glands & Others

Glaucoma:

• Comparison of Burden of Care and Visual Field Progression between Newly Diagnosed Glaucoma Patients Managed on Topical Monotherapy and Those Who Switch or Add On Therapies
  • Date and Time: Monday, May 2, 2016, 3:45-5:30 PM
  • Room: Main Exhibit Hall
  • Categories: Glaucoma

• A Multicenter Study Assessing Inter-Examiner Agreement of Gonioscopic Shaffer Grading in Patients with Open-Angle Glaucoma and/or Ocular Hypertension
  • Date and Time: Tuesday, May 3, 2016, 8:30-10:15 AM
  • Room: Main Exhibit Hall
  • Categories: Glaucoma Clinical Studies/Pharmacology

• Additive ocular hypotensive effects of Bimatoprost Sustained-Release intracameral implant on potent topical therapy in monkeys
  • Date and Time: Tuesday, May 3, 2016, 8:30-10:15 AM
  • Room: Main Exhibit Hall
  • Categories: Glaucoma Clinical Studies/Pharmacology

• Intracameral Administration of a Sustained Release Bimatoprost Implant Efficiently Delivers Bimatoprost to Target Tissue Reducing Risk of Topical Prostaglandin Analog- Associated Adverse Events
  • Date and Time: Tuesday, May 3, 2016, 8:30-10:15 AM
  • Room: Main Exhibit Hall
  • Categories: Glaucoma Clinical Studies/Pharmacology

• Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 12-Month Interim Results From a Phase 1/2 Clinical Trial
  • Date and Time: Wednesday, May 4, 2016, 9:00-9:15 AM
  • Room: 6A
  • Categories: Glaucoma Clinical Studies

• A Quantitative Assessment of the Iridocorneal Angle in Asian Patients with Open-angle Glaucoma or Ocular Hypertension Using Schwalbe's Line-based Angle Biometrics
  • Date and Time: Wednesday, May 4, 2016, 11:00 AM-12:45 PM
  • Room: Main Exhibit Hall
  • Categories: Glaucoma Imaging II

• Subsequent medical management of open-angle glaucoma patients treated with laser trabeculoplasty
  • Date and Time: Wednesday, May 4, 2016, 3:45-5:30 PM
  • Room: Main Exhibit Hall
  • Categories: Glaucoma Lasers, Surgery, & IOP

• Comparative Ocular Distribution of ¹⁴C-Latanoprost Following a Single Intracameral or Repeated Topical Ocular Dose in Dogs
  • Date and Time: Wednesday, May 4, 2016, 3:45-5:30 PM
  • Room: Main Exhibit Hall
  • Categories: Glaucoma Potpourri

About Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world. 

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:      

Investors:
Lisa DeFrancesco 
(862) 261-7152

Media:  
Mark Marmur
(973) 906-1526

SOURCE Allergan plc

Related Links

http://www.allergan.com